Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596762 · ClinicalTrials.gov registry record · Phase 2
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT03596762 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 199 participants.
The verdict
NCT03596762, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
Interventions
- DRUG Placebo
- DRUG Elinzanetant (BAY3427080)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2019-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596762
The ClinicalTrials.gov registry entry for NCT03596762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03596762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596762 about?
NCT03596762 is a clinical study titled "A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms". The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
What is the current status of trial NCT03596762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2018-11-20. Estimated completion is 2019-11-21.
What interventions are being tested in trial NCT03596762?
The interventions under investigation include: Placebo (DRUG), Elinzanetant (BAY3427080) (DRUG).
Who is sponsoring clinical trial NCT03596762?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.